Related Experiment Video
Updated: May 24, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.7K
Prognostic predictors of newly diagnosed Diffuse large B-cell lymphoma treated with R-THP-COP regimen
Yoshiaki Okano1, Tatsuo Oyake1, Sawako Kitamura1
1Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Summary
The National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) effectively predicts outcomes for Diffuse Large B-cell Lymphoma (DLBCL) patients treated with R-THP-COP chemotherapy. This prognostic tool helps identify patients with a poor prognosis, guiding treatment decisions.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Established prognostic models like the International Prognostic Index (IPI) are used for malignant lymphomas.
- The applicability of these models to R-THP-COP chemotherapy is not well-defined.
Purpose of the Study:
- To evaluate the prognostic value of IPI, R-IPI, and NCCN-IPI in Diffuse Large B-cell Lymphoma (DLBCL) patients treated with R-THP-COP.
- To assess the effectiveness of these indices in predicting patient outcomes.
Main Methods:
- Retrospective analysis of 101 DLBCL patients treated with R-THP-COP.
- Evaluation of overall survival (OS), progression-free survival (PFS), and complete response rate (CRR).
- Assessment of IPI, revised IPI (R-IPI), and National Comprehensive Cancer Network IPI (NCCN-IPI) for risk prediction.
Main Results:
- Five-year OS was 67% and PFS was 58.9%.
- Complete response rate (CRR) was 63.5%.
- All evaluated prognostic indices (IPI, R-IPI, NCCN-IPI) demonstrated predictive value for patient outcomes.
Conclusions:
- The NCCN-IPI is the most effective prognostic tool for identifying DLBCL patients with poor prognosis.
- Prognostic models, particularly NCCN-IPI, remain valuable for patients treated with R-THP-COP chemotherapy.
